Cell therapy-focused biotech company NeoStem (NYSE:NBS) announced Thursday that its management will present at six conferences in June.
The company will present at the International Society for Cellular
Therapy Annual Meeting, the National Investment Banking Association
Conference, the International Society for Stem Cell Research 10th Annual
Meeting, the Biotechnology Industry Organization (BIO )International
Conference, the Alliance for Regenerative Medicine -- Clinical Outlooks
for Regenerative Medicine 2012, and lastly, the Marcum's Inaugural
MicroCap Conference.
The International Society for Cellular Therapy Annual Meeting will be
hosted on June 6th and June 8th at the Sheraton Seattle, in Seattle,
Washington.
The conference taking place on June 6th will be held at 6:00 pm (PDT). NeoStem’s
presenter is Robert A. Preti, the president and chief scientific
officer of Progenitor Cell Therapy (PCT). He will give a presentation
entitled “On the Entrepreneurial Challenges of Cell Therapy.”
The conference taking place on June 8th will be held at 1:15 pm (PDT). NeoStem’s
presenter is Timothy Fong, the vice president of technology and product
development of PCT. He will give a presentation entitled “From
Product: the Pathway from Academic Innovation to a Commercial
Manufacturing Process.”
Meanwhile, the National Investment Banking Association Conference
will be hosted on June 7th at 10:00 AM (EDT) at the Le Parker Meridien
Hotel, in New York, New York. The presenter will be Robin L. Smith, NeoStem’s chairman and CEO.
The International Society for Stem Cell Research 10th Annual Meeting
will be hosted on June 15th at 6:00 PM (JST) at the Pacifico Yokohama,
in Yokohama, Japan. The presenters will be Denis Rodgerson, NeoStem’s
director of stem cell science, and Aaron M. Havens of the University of
Michigan. The team will present a poster entitled “First Demonstration
That Human Very Small Emryonic-Like (VSEL) Stem Cells Can Regenerate
Human Bone in a Model of Skeletal Repair.”
The Biotechnology Industry Organization (BIO) International
Conference will be hosted on June 19th at 9:15 AM (EDT) at the Boston
Convention & Exhibition Center, in Boston, Massachusetts. The
presenter will again be CEO Smith.
The Alliance for Regenerative Medicine -- Clinical Outlooks for
Regenerative Medicine 2012 will be hosted on June 19th at 2:45 PM (EDT)
at the Starr Center, Schepens Eye Research Institute, in Boston,
Massachusetts. The presenter will be Jonathon Sackner-Bernstein, vice
president of clinical development and regulatory affairs. He will
present on the cardiovascular panel about the company's treatment
Amorcyte.
Finally, the Marcum's Inaugural MicroCap Conference will be hosted on
June 20th at the Roosevelt Hotel, in New York, New York, with Smith
presenting.
NeoStem’s
aim is to become a single source for the collection, storage,
manufacturing, therapeutic development and transportation of cells for
cell-based medicine.
The company most recently appeared in Bloomberg Television’s "Talking
Stock" on May 14th, where CEO Smith discussed the company’s latest stem
cell therapy trial testing a regenerative therapy for heart attack
survivors.
The treatment uses an autologous bone marrow-derived stem cell called
CD34, to limit the damage of heart muscle that develops following an
acute heart attack and prevents ventricular remodeling, which is the
accepted mechanism responsible for clinical progression and increased
risk.
Smith said the company plans to have results from the trial in 2013.
The company released its first quarter results earlier in May, saying it had increased revenues by 13 per cent.
Revenue rose to $22.1 million from $19.6 million, while the
underlying loss for the three months to March was $2.7 million,
excluding non-cash charges.
The company also owns a 51 percent stake in a Chinese generic
pharmaceutical manufacturing company Suzhou Erye Pharmaceutical, and is
looking to sell its stake in Suzhou to bolster its cell therapy
business.
NeoStem also has a network of stem cell therapeutic providers in China.
No comments:
Post a Comment